A protein found in immune cells may be a reliable marker for schizophrenia risk, report researchers in a new proteomics study appearing in the July issue of Molecular and Cellular proteomics.
Schizophrenia is a severe and complex psychiatric illness that affects about 1% of the population. Diagnosis currently relies on subjective clinical interviews and the assessment of ambiguous symptoms, which frequently leads to delayed diagnosis and treatment. As such, biomarkers that would indicate schizophrenia risk or onset would be extremely useful.
Sabine Bahn and colleagues sought to find such a "protein fingerprint" in the blood (due to its accessibility). They compared protein profiles of schizophrenia patients and controls using mass spectrometry and identified two peaks highlighting a significant change. These were identified as alpha defensins, proteins responsible for killing microbes and viruses in the innate immune response.
Bahn and colleagues confirmed their findings by examining alpha defensin levels in the blood of 21 twin pairs discordant for schizophrenia (where one sibling manifests the disease while the other does not). In these twin sets, both siblings had significantly elevated alpha defensins as compared with a group of control twins. Changes were also found in patients who were investigated soon after diagnosis, which means that higher levels of alpha defensins were not caused by medication or progression of the disease.
Source: American Society for Biochemistry and Molecular Biology
Related stories:
Immaturity of the brain may cause schizophrenia
The underdevelopment of a specific region in the brain may lead to schizophrenia in individuals. According to research published today in BioMed Central's open access journal
Molecular Brain, dentate gyrus, which is located in the hippocampus in the brain and thought to be responsible for working memory and mood regulation, remained immature in an animal model of schizophrenia.
Biophysicists create new model for protein-cholesterol interactions in brain and muscle tissue
Biophysicists at the University of Pennsylvania have used 3,200 computer processors and long-established data on cholesterol's role in the function of proteins to clarify the mysterious interaction between cholesterol and neurotransmitter receptors. The results provide a new model of behavior for the nicotinic acetylcholine receptor, a well studied protein involved in inflammation, Alzheimer's disease, Parkinson's disease, schizophrenia, epilepsy, the effect of general anesthetics and addiction to alcohol, nicotine and cocaine.
Protein found that regulates gene critical to dopamine-releasing brain cells
Researchers have identified a protein they say appears to be a primary player in maintaining normal functioning of an important class of neurons – those brain cells that produce, excrete and then reabsorb dopamine neurotransmitters. These molecules command numerous body functions, ranging from management of behavior and mood to control of movement, and one day may hold the key to why and how some people develop Parkinson's and other brain diseases.
Researchers piece together gene 'network' linked to schizophrenia
Reporting this week in the Archives of General Psychiatry, researchers at the Johns Hopkins University School of Medicine have uncovered for the first time molecular circuitry associated with schizophrenia that links three previously known, yet unrelated proteins.
Looking beyond the drug receptor for clues to drug effectiveness
Antipsychotic drugs that are widely used to treat schizophrenia and other problems may not work as scientists have assumed, according to findings from Duke University Medical Center researchers that could lead to changes in how these drugs are developed and prescribed.
Trigger for brain plasticity identified
Researchers have long sought a factor that can trigger the brain's ability to learn – and perhaps recapture the "sponge-like" quality of childhood. In the August 8 issue of the journal
Cell, neuroscientists at Children's Hospital Boston report that they've identified such a factor, a protein called Otx 2.
Researchers discover how antidepressants and cocaine interact with brain cell targets
In a first, scientists from Weill Cornell Medical College and Columbia University Medical Center have described the specifics of how brain cells process antidepressant drugs, cocaine and amphetamines. These novel findings could prove useful in the development of more targeted medication therapies for a host of psychiatric diseases, most notably in the area of addiction.
Incorrectly cleaved protein leads to schizophrenia
Schizophrenia is a disease that strikes an average of 4000 Belgians every year. The causes of this psychiatric disorder are not yet clear. But now, VIB researchers connected to the Katholieke Universiteit Leuven have discovered that a disturbed cleavage of the Nrg-1 protein lies at the basis of the development of the disease. Greater understanding of this molecular process is a first step toward improved diagnosis and more effective treatment of schizophrenia and other related disorders.